On Apr. 9, 2020, CytoDyn announced a patient with severe COVID-19 under the care of a leading medical center in Southern California exhibited clinical improvement after treatment with the Company;s investigational new drug, leronlimab. The patient was intubated and in critical condition in the ICU, and had received an IL-6 blocking agent four days earlier without apparent benefit. Concomitantly, the patient also received either an antiretroviral agent or placebo as part of an unrelated clinical trial.

With no clinical improvement observed over the ensuing four days, the patient then received leronlimab. Within twenty-four hours, the patient showed significant clinical improvement and was removed from external ventilation three days later. This outcome is consistent with that observed in severely ill COVID-19 patients treated with leronlimab at a leading medical center in New York City.